COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,971 Articles (22,604 medRxiv, 8,367 bioRxiv)

Most recent first Previous |  Page 1719: Articles 17181-17190  | Next

Redesigning SARS-CoV-2 clinical RT-qPCR assays for wastewater RT-ddPCR
Gonzalez, R. A., Larson, A., Thompson, H., Carter, E., Cassi, X. F.
10.1101/2021.03.02.21252754 — Posted: 2021-03-05
Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers
Lundstrom, A., Ziegler, L., Havervall, S., Rudberg, A.-S., Meijenfeldt, F. V., Lisman, T., Mackman, N., Sanden, P., Thalin, C.
10.1101/2021.03.03.21252841 — Posted: 2021-03-05
Virological and serological characterization of critically ill patient with COVID-19 in the UK: a special focus on variant detection
Ratcliff, J., Nguyen, D., Fish, M., Rhynne, J., Jennings, A., Williams, S., Al-Beidh, F., Bonsall, D., Ciccone, N., Evans, A., Golubchik, T., Gordon, A. C., Lamikanra, A., Laing, E., Leuscher, U., Mouncey, P. R., Olivera, M., Slack, W., Tsang, P., Ziyenge, S., Ploeg, R., Rowan, K. M., Shankar-Hari, M., Roberts, D., Menon, D. K., Estcourt, L., Simmonds, P., Harvala, H., REMAP-CAP Immunoglobulin Domain UK Investigators
10.1101/2021.02.24.21251989 — Posted: 2021-03-05
COVID Seroprevalence, Symptoms and Mortality During the First Wave of SARS-CoV-2 in Canada
Action to beat coronavirus/Action pour battre le coronavirus (Ab-C) Study Investigators, , Jha, P.
10.1101/2021.03.04.21252540 — Posted: 2021-03-05
COVID-19 test positivity: predictive value of various symptoms in a large community-based testing program in California
Miller, D. P., Morrow, S., Califf, R. M., Kaiser, C., Kapur, R., Starsiak, C., Mega, J., Marks, W. J.
10.1101/2021.03.03.21252014 — Posted: 2021-03-05
Association between SARS-CoV-2 Transmission Risk, Viral Load, and Age: A Nationwide Study in Danish Households
Lyngse, F. P., Molbak, K., Franck, K. T., Nielsen, C., Skov, R. L., Kirkeby, C. T.
10.1101/2021.02.28.21252608 — Posted: 2021-03-05 Discussion: Onsite
Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic
Sughayer, M. A., Mansour, A., Al Nuirat, A., Souan, L., Ghanem, M., Siag, M.
10.1101/2021.03.02.21252448 — Posted: 2021-03-05
Clinical course and risk factors for in-hospital mortality of 205 patients with SARS-CoV-2 pneumonia in Como, Lombardy Region, Italy
Turrini, M., Gardellini, A., Beretta, L., Buzzi, L., Ferrario, S., Vasile, S., Clerici, R., Colzani, A., Liparulo, L., Scognamiglio, G., Imperiali, G., Corrado, G., Strada, A., Galletti, M., Castiglione, N., Zanon, C.
10.1101/2021.02.25.20134866 — Posted: 2021-03-05
Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in communities
Yang, Q., Saldi, T. K., Lasda, E., Decker, C. J., Paige, C. L., Muhlrad, D. G., Gonzales, P. K., Fink, M. R., Tat, K. L., Hager, C. R., Davis, J. C., Ozeroff, C. D., Meyerson, N. R., Clark, S. K., Fattor, W. T., Gilchrist, A. R., Barbachano-Guerrero, A., Worden-Sapper, E. R., Wu, S. S., Brisson, G. R., McQueen, M. B., Dowell, R. D., Leinwand, L. A., Parker, R. R., Sawyer, S.
10.1101/2021.03.01.21252250 — Posted: 2021-03-05
Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination
Müller, L., Andree, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., Rabl, D., Ostermann, P. N., Robitzsch, R., Hauka, S., Walker, A., Menne, C., Grutza, R., Timm, J., Adams, O., Schaal, H.
10.1101/2021.03.03.21251066 — Posted: 2021-03-05 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).